Silence Therapeutics RNAi Lead Compound Atu027 Successfully Completes 28-Day Toxicology Studies
The Company also confirms that, following discussions with the United States Patent and Trademark Office, it is progressing its core AtuRNAi patent application in the USA. Silence Therapeutics was granted its core chemistry patent (EP 1527176) by the European Patent Office in January 2007.
"These results represent a significant step for us in the development of our systemically delivered, proprietary AtuRNAi molecules," said Jeff Vick, Chief Executive Officer of Silence Therapeutics. "The delivery of siRNA molecules as a whole, and systemic delivery in particular, is an important challenge upon which the industry is focussed. We are delighted that we have been able to announce our progress and look forward to working independently and with our pharmaceutical partners to bring our proprietary siRNA molecules, combined with proprietary delivery technologies, into the clinic in 2008 and beyond. In addition we anticipate that our products and technologies will have broad international patent protection."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.